A Phase 3 interventional study of Low-intensity Extracorporeal Shock Wave Therapy (LiESWT) and PDE5 inhibitor (tadalafil) in Prostate Carcinoma, Erectile Function and Genito Urinary Cancer, sponsored by Regina Elena Cancer Institute. Recruiting at 2 sites in Italy. Open to male participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-14.
Sponsored by Regina Elena Cancer Institute · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Prostatic Neoplasms by Regina Elena Cancer Institute — 4 open to participants now, 5 under way, 1 of them phase 3. Prostatic Neoplasms · Regina Elena Cancer Institute.
Among the 10 studies in Prostatic Neoplasms by Regina Elena Cancer Institute, this one is the only one that started in 2023, is the only one in phase 3, and was the 7th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →4 of the 10 studies in Prostatic Neoplasms by Regina Elena Cancer Institute are open now, in 1 country. Recruiting first, the newest first:
Regina Elena Cancer Institute · Sites in Italy
Ages 18–99 · Men only
Regina Elena Cancer Institute · Sites in Italy
Men only
Regina Elena Cancer Institute · Sites in Italy
Ages 18–90 · Men only
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years to 75 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 158 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 125 across the 8 interventional studies, 93 across the 2 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Regina Elena Cancer Institute is the lead sponsor of 95 studies on the registry; 51 are open to participants now.
3 of the studies in Prostatic Neoplasms by Regina Elena Cancer Institute that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06717711Phase 3Regina Elena Cancer InstituteLow-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Robot-assisted Surgical Treatment of Genitourinary Cancers | 2027-02-28 |
| NCT06891664Regina Elena Cancer InstituteFeasibility of Day-surgery Management for Patients Undergoing Robotic Radical Prostatectomy: a Randomized Trial | 2027-05-23 |
| NCT06894628Regina Elena Cancer InstituteGenomics and Efficacy of Post-prostatectomy Salvage Radiotherapy With 'Extreme' Hypofractionation | 2027-11-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies in Prostatic Neoplasms by Regina Elena Cancer Institute, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This prospective randomized controlled trial (RCT) is designed to provide high level evidence on the efficacy of Low-intensity Extracorporeal Shock Wave Therapy (Li-ESWT) in the treatment of post-Robot-Assisted (RA) Radical Prostatectomy (RP) erectile dysfunction (ED) in addition to PDE5 inhibitors (PDE5i) versus PDE5i alone. Our hypothesis is that early andrological rehabilitation that combines Li-ESWT and PDE5i could lead to faster and better recovery of valid erections for intercourse, with a greater rate of postoperative International Index of Erectile Function-5 (IIEF-5) compared to patients receiving PDE5i alone.
Background / State of Art ED is a common complication after radical prostatectomy, with a prevalence ranging from 40% to 80% of patients 1,2.
This considerable variability depends on the degree (intrafascial vs interfascial) and laterality (unilateral vs bilateral) of nerve sparing performed, as well as the surgical approach.
There is still paucity of high-level evidences in terms of impact of surgical approach on postoperative outcomes after RP. Considering the same surgical approach, technique, surgeon experience, patient age and preoperative erectile function remain the main predictors of postoperative sexual function.
In this context rehabilitation is still debatable and there is a lack of clear recommendations regarding the use of PDE5i and other forms of therapy. However, a multi-centre double blind RCT (n = 423) in men aged \< 68 years, with normal pre-treatment erectile function undergoing either open, conventional or robot-assisted laparoscopic nerve-sparing RP, tadalafil (5 mg) once per day improved participants EPIC (Expanded Prostate Cancer Index Composite) sexual domain-scores (least squares mean difference +9.6, 95% CI: 3.1-16.0) when compared to 20 mg 'on demand' or placebo at 9 months of follow-up 3. As a result, there has been a trend toward early use of PDE5i after RP as demonstrated in some studies 4.
Hypothesis and specific aims Hypothesis and Significance The use of nerve-sparing techniques during robotic surgery has been shown to improve recovery of erectile function. However, some patients still experience ED after undergoing bilateral nerve-sparing RARP. Possible causes can be the mechanical stretching or thermal damage to cavernous nerves, ischemic injuries or local inflammation caused by surgery itself 5. Moreover, after surgery this condition could be exacerbated by an increased fibrosis and decreased elasticity of the erectile tissue in the corpora cavernosa.
Current sexual rehabilitation is essentially based on PDE5i which have been shown to increase levels of cyclic GMP in penile smooth muscle cells, preserving smooth muscle content and reducing corpora cavernosa fibrosis 6,7. At the same time, the use of vacuum erection devices, intraurethral suppositories and intracavernous injections do not guarantee an optimal penile rehabilitation after RP 8.
In this scenario, LiESWT has been recently introduced, showing promising results 9,10. It differs from other ED treatments, due to its action on the underlying pathophysiology of ED 11, offering a local remodelling of the erectile tissue 12.
Different types of energies can be used for LiESWT. The electro-hydraulic or electromagnetic generator deliver sound waves directed to the corpora cavernosa and crura, at an energy density of around 0.09 mJ/mm². Another source of energy used for LiESWT is the piezo shockwave therapy. Piezo-ceramic elements are geometrically arranged on a concave surface so that when they are excited simultaneously by a brief, high-voltage pulse, they expand by a few micrometers to generate a pressure pulse. The piezo elements are precisely aligned so that each pressure pulse generated focuses in a specific area. This precise focusing of the pulse creates a shockwave at the point of focus. The piezo shockwave's "direct focusing" technology eliminates the need for additional reflectors, resulting in a compact therapy source design and a precise and well-defined focal zone. The virtually painless therapy is quiet and energy levels can be freely adjusted with almost no adverse effect on the size of the focal zone. Extracorporeal shockwaves are mechanical stressors capable of inducing biochemical changes in living tissue; at a molecular level these changes can influence gene expression in cells and, if used selectively, can produce specific reactions in tissue. This process is referred to as mechanotransduction. The therapy was first tested for vasculogenic ED in 2010 by Vardi et al. due to its potential to promote neovascularization in the myocardium 13,14. LiESWT has also been recognized to increase nitric oxide synthesis in penile tissue and supports stem cell proliferation 15. Multiple meta-analyses suggested that LiESWT is an effective treatment for ED, resulting in an improvement in the erectile function domain scores of IIEF-5, playing a significant role not only in vasculogenic ED (neoangiogenesis) but also in neurogenesis 16,17.
However, despite the promising results, there is still a lack of high-level evidences on the use of LiESWT for ED, especially in the specific setting of postoperative rehabilitation after RP.
Our hypothesis is that LiESWT in addition to PDE5i administration could improve sexual rehabilitation with faster recovery of valid erection and higher IIEF-5 scores in the short and medium-term follow-up.
OBJECTIVES:
Primary Objective
ED remains a significant issue after radical prostatectomy, with some of the most reliable data on patient-reported outcome measures (PROMs), including erectile function, coming from the Prostate Testing for Cancer and Treatment (ProtecT) trial. The worst trend over time was observed in the RP group, with only 21% of patients reporting erections firm enough for intercourse after 3 years, and 17% after 6 years 18. However, data regarding optimal postoperative rehabilitation of ED are still limited. The International Index of Erectile Function short form (IIEF-5) questionnaire is the recognized tool for evaluating erectile function both preoperatively and during follow-up.
The primary endpoint of this study is to determine if the difference in the final mean IIEF-5 score at last follow-up, favours the use of LiESWT in combination with PDE5i compared to early PDE5i alone for penile rehabilitation after RARP, with a minimum clinically important difference (MCID) of at least 4 points 19.
Secondary Objectives
Subgroup analysis An exploratory subgroup analysis will be conducted to evaluate the efficacy of LiESWT for the treatment of ED also in patients at intermediate risk PCa and in patients undergoing radical cystectomy.
STUDY DESIGN Prospective randomized controlled trial (RCT) designed to provide high level evidences describing the role of LiESWT plus early introduction of PDE5i vs early PDE5i alone on penile rehabilitation of ED after RARP.
STUDY POPULATION
Inclusion criteria:
Exclusion criteria:
Methodologies All patients for whom eligibility criteria have been verified will be enrolled and randomized by the Promoter.
Then, patients will be randomized into:
Patients were allocated 1:1 in each group. RARP will be performed according to EAU guidelines 21.
ASSESSMENTS Both arms will start tadalafil at a dose of 5mg/day right after the removal of the transurethral catheter, which occurs between the 7th and 10th postoperative days. All patients will receive 5 mg tadalafil tablets (7 per week), which will be dispensed weekly at each follow-up visit. Patients will be monitored for continence status (measured by pads/days), sexual function (IIEF-5 and EHS scores), and possible adverse events.
Forty-five days (45d) after surgery, the first measure of PSA will be performed.
If PSA results \<0.2 ng/ml patients will be randomized. The LiESWT (6-week period) will begin one week after PSA evaluation (52d after surgery). LiESWT will be performed with PiezoWave2 from Richard Wolf and ELvation® Medical. In a single session 12,000 shocks with an energy flux density of 0.16 mJ/mm2 will be applied (4,000 over the crura of the penis and 8,000 to the penil shaft). The penis is placed in a dedicated penile holder, stretched, and shockwaves are administered with a linear therapy source (applicator) using the linear shockwave tissue coverage (LSTC-ED®) technique which makes it possible to administer shockwaves homogenously to all of the erectile tissue. Specific adverse effects that could be related to LiESWT, such as hematomas, local pain, and neuropraxia, will be assessed, classified, and recorded. Therefore, at the last follow-up, 94 days after surgery (3mo after surgery) the final IIEF-5 and EHS scores will be assessed. Afterwards, IIEF-5 and EHS scores will be collected 6 and 12 mo after surgery.
After 1 yr from surgery both groups will be asked to stop PDE5i for 2 weeks (washout period) and then IIEF-5 and EHS score will be collected without PDE5i treatment.
Each treatment will be performed in accordance with the most recent scientific evidence and European guidelines, according to oncologic departments; adverse events will be managed according to normal clinical practice.
Erectile function and HRQoL assessment Erectile function will be assessed using IIEF-5 and EHS scores, pre- and postoperatively. HRQoL will be tested before surgery and at 3-, 6- and 12-months (mo) follow-up evaluation through a self-administered validated questionnaire (EORTC-QLQ-C30 and QLQ-BLM30).
CLINICAL DATA
The following data will be collected and analysed for each patient:
SAMPLE SIZE AND STATISTICAL CONSIDERATION According to previous studies, 4-points of difference between the final IIEF-5 means is the minimal clinically important difference (MCID) in the EF domain of the IIEF-5 scale 19. Therefore, considering a standard deviation of 9 (calculated on a previous pilot study), a power of 0.80 and α (2-sided) of 0.05, a sample size of 158 patients (79 for each cohort) is needed to test our hypothesis.
The continuous data as mean and standard deviation or median and range will be reported. Binary data will be reported as frequency and percentage values. ANOVA with repeated measures will be used for estimate primary endpoint. Student's paired t-test will be used to compare mean values, when appropriate. A p-value ≤ 0.05 will be considered statistically significant. The statistical analysis program SPSS V21 (SPSS Inc., Chicago, IL) will be used.
RANDOMIZATION Participants will be randomly assigned to group 1 or 2, based on a computer-generated randomization schedule prepared before the study by the Promoter.
Randomization is centralized and will be generated by an independent group of the promoter.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receiving LiESWT plus early introduction of PDE5i
Device: Low-intensity Extracorporeal Shock Wave Therapy (LiESWT) · Drug: PDE5 inhibitor (tadalafil)
Control group, patients receiving PDE5i alone
Drug: PDE5 inhibitor (tadalafil)
LiESWT will be performed with PiezoWave2 from Richard Wolf and ELvation® Medical. In a single session 12,000 shocks with an energy flux density of 0.16 mJ/mm2 will be applied (4,000 over the crura of the penis and 8,000 to the penil shaft). The penis is placed in a dedicated penile holder, stretched, and shockwaves are administered with a linear therapy source (applicator) using the linear shockwave tissue coverage (LSTC-ED®) technique which makes it possible to administer shockwaves homogenously to all of the erectile tissue.
Phosphodiesterase-5 (PDE5) inhibitors
Erectile Function
To investigate the impact of LiESWT in combination with early PDE5i administration versus early PDE5i alone on the penile rehabilitation of erectile dysfunction (ED) after RARP
Time frame: From enrollment to 1 year after treatment
Urinary Continence
To evaluate the impact of LiESWT on continence status.
Time frame: From enrollment to 1 year after treatment
Adverse effects
To report any adverse effects and classify them according to the Clavien Dindo classification
Time frame: From enrollment to 1 year after treatment
Health Related Quality of Life
To compare health-related quality of life (HRQoL) outcomes at 3-, 6- and 12-months (mo) follow-up post-surgery
Time frame: From enrollment to 1 year after treatment
Plan to share: No
Started Sep 2023 (actual). Primary completion is estimated for Feb 2027, 41 months after the start.
Of 139 non-industry phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 99 months of starting (the median), counting those still running; a quarter within 57 and three quarters within 144. This study's planned 41 months is below that.
Counting every sponsor, half of 266 studies reached it within 57 months; a quarter within 31 and three quarters within 100.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Regina Elena Cancer Institute